Business
These responsibilities are outlined in SOPs. The
study director, facility management and archivist roles are equally applied to non-GLP studies.
l Any corrective actions taken to protocols or SOPs and any GLP deviations must be documented. lOne study director is responsible for the conduct of each GLP-compliant or non-GLP study and acts as the study’s single point of control. l The quality assurance unit (QAU) monitors GLP studies, reporting to management and the study director. The QAU does not monitor all non-GLP studies or records; however, the QAU does perform facility and process-based inspections of all facility operations to ensure that no deviations were made without proper documentation and authorisation. The QAU also maintains copies of all GLP-compli- ant and non-GLP audited protocols and a master schedule sheet (MSS) of all GLP-compliant and non-GLP audited studies conducted at the facility.
Facilities l As per GLP regulations, adequate facilities must be provided for each study. l Adequate, procedure-specific laboratory areas contain: m Test article and control article receipt and storage
m Test article and control article storage m Solution preparation m Microsome preparation
64
m LC-MS-MS analysis m Sterile and aseptic procedures m Biohazard procedures
l On-site facility archives should be maintained, but specimen archives are not required. At the close of a study, specimens may be shipped to the sponsor or another, designated storage location. Or, they may be disposed of at the sponsor’s request. These procedures are the same for both GLP-compliant and non-GLP studies.
Standard operating procedures l SOPs covering laboratory operations as listed in the GLP regulations are maintained. These proce- dures cover both in vitro and ex vivo studies. l Additional SOPs cover experimental methods and procedures appropriate for specific studies (ie drug metabolism and drug interaction studies). l Management must approve all new and revised SOPs. l An archive is maintained for all historical ver- sions of SOPs. lHard copies are available in laboratories and elec- tronic SOPs are available at all workstations. With a few exceptions, the same SOPs support the conduct of both GLP-compliant and non-GLP studies.
Equipment l Study personnel may use the same laboratories and equipment for all contracted studies. Thus maintenance, calibration, testing and record keep-
Drug Discovery World Winter 2018/19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68